{"id":46628,"date":"2022-07-27T14:02:13","date_gmt":"2022-07-27T12:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/"},"modified":"2022-07-27T14:02:13","modified_gmt":"2022-07-27T12:02:13","slug":"cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/","title":{"rendered":"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022"},"content":{"rendered":"
\n

\nNew ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$CRTX<\/a>–Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company\u2019s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics\u2019 go-forward growth strategy and development pipeline plans.\n<\/p>\n

<\/a><\/p>\n

\nAdditionally, the company\u2019s ticker symbol on the Nasdaq Global Select Market is expected change to \u201cQNCX\u201d effective at the open of market trading on Monday, August 1, 2022. The company\u2019s common stock will continue to trade under the ticker symbol \u201cCRTX\u201d until market close on Friday, July 29, 2022. The corporate name change to Quince Therapeutics does not affect the rights of the company\u2019s stockholders. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.\n<\/p>\n

\nQuince Therapeutics also plans to launch its new corporate website and social media presence on Twitter and LinkedIn on Monday, August 1, 2022.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nStatements in this news release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast,\u201d or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our anticipated corporate name change and related timing. Forward-looking statements are based on Cortexyme\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled \u201cRisk Factors\u201d in Cortexyme\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCortexyme Contact:<\/b>
Stacy Roughan
\n
Cortexyme, Inc.
\n
Vice President, Corporate Communications & Investor Relations
\n
ir@cortexyme.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$CRTX–Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company\u2019s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46628","6":"format-standard","7":"category-industry"},"yoast_head":"\nCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$CRTX–Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company\u2019s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-27T12:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220727005263\/en\/1091862\/21\/logo_large_jpg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022\",\"datePublished\":\"2022-07-27T12:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/\"},\"wordCount\":418,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005263\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/\",\"name\":\"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005263\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\",\"datePublished\":\"2022-07-27T12:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005263\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005263\\\/en\\\/1091862\\\/21\\\/logo_large_jpg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/","og_locale":"en_US","og_type":"article","og_title":"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Pharma Trend","og_description":"New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$CRTX–Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company\u2019s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-27T12:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220727005263\/en\/1091862\/21\/logo_large_jpg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022","datePublished":"2022-07-27T12:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/"},"wordCount":418,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005263\/en\/1091862\/21\/logo_large_jpg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/","url":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/","name":"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005263\/en\/1091862\/21\/logo_large_jpg.jpg","datePublished":"2022-07-27T12:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220727005263\/en\/1091862\/21\/logo_large_jpg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220727005263\/en\/1091862\/21\/logo_large_jpg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cortexyme-corporate-name-change-to-quince-therapeutics-to-take-effect-on-august-1-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46628"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46628\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}